Investment Counsel Inc. reduced its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 7.8% during the second quarter, according to its most recent filing with the SEC. The fund owned 26,642 shares of the biopharmaceutical company’s stock after selling 2,240 shares during the quarter. Investment Counsel Inc.’s holdings in Bristol-Myers Squibb were worth $1,484,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BMY. Blue Chip Partners Inc. increased its position in Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares during the last quarter. Keel Point LLC lifted its position in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock valued at $342,000 after buying an additional 18 shares during the last quarter. Staley Capital Advisers Inc. lifted its position in shares of Bristol-Myers Squibb by 0.3% during the 1st quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the last quarter. Shayne & CO. LLC lifted its position in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 24 shares during the last quarter. Finally, Founders Capital Management LLC grew its stake in shares of Bristol-Myers Squibb by 0.7% during the 1st quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 29 shares during the period. 68.88% of the stock is currently owned by institutional investors.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company (NYSE BMY) opened at 64.56 on Tuesday. The stock’s 50 day moving average price is $60.77 and its 200 day moving average price is $56.42. The stock has a market cap of $105.87 billion, a price-to-earnings ratio of 23.58 and a beta of 1.19. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $64.78.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.69 earnings per share. Equities analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.

Several equities research analysts recently weighed in on BMY shares. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective for the company in a report on Wednesday, September 27th. Jefferies Group LLC restated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $65.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a report on Friday, September 8th. Finally, Hilliard Lyons lowered shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a research report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $62.17.

ILLEGAL ACTIVITY WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/03/bristol-myers-squibb-company-bmy-shares-sold-by-investment-counsel-inc.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.